Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valerio Nardone

Showing results (131-140 of 139) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 139 results.
Frontiers in Oncology|December 6, 2021
Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung CancerAlessio Bruni, Vieri Scotti, Paolo Borghetti, et al.
Frontiers in Oncology|October 15, 2021
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung CancerAlessio Bruni, Vieri Scotti, Paolo Borghetti, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockadePierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Diagnostics (Basel, Switzerland)|February 11, 2023
Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer PatientsValerio Nardone, Alfonso Reginelli, Giuseppina De Marco, et al.
Frontiers in Oncology|November 30, 2019
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-UpMichele Caraglia, Pierpaolo Correale, Rocco Giannicola, et al.
The British Journal of Dermatology|December 13, 2023
Indications for adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma with clear margins: a Delphi consensusElvira Moscarella, Eugenia Veronica Di Brizzi, Paolo Alpi, et al.
Frontiers in Immunology|May 4, 2026
Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world studyFrancesco Caraglia, Giuseppe Argenziano, Marcella Scala, et al.
Iscience|March 4, 2025
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerCaterina De Rosa, Floriana Morgillo, Luisa Amato, et al.
Frontiers in Immunology|February 2, 2024
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern ItalyVito Longo, Carminia Maria Della Corte, Alessandro Russo, et al.
Pageof 14

Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Frontiers in Oncology|December 6, 2021
Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung CancerAlessio Bruni, Vieri Scotti, Paolo Borghetti, et al.
Frontiers in Oncology|October 15, 2021
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung CancerAlessio Bruni, Vieri Scotti, Paolo Borghetti, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockadePierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Diagnostics (Basel, Switzerland)|February 11, 2023
Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer PatientsValerio Nardone, Alfonso Reginelli, Giuseppina De Marco, et al.
Frontiers in Oncology|November 30, 2019
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-UpMichele Caraglia, Pierpaolo Correale, Rocco Giannicola, et al.
The British Journal of Dermatology|December 13, 2023
Indications for adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma with clear margins: a Delphi consensusElvira Moscarella, Eugenia Veronica Di Brizzi, Paolo Alpi, et al.
Frontiers in Immunology|May 4, 2026
Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world studyFrancesco Caraglia, Giuseppe Argenziano, Marcella Scala, et al.
Iscience|March 4, 2025
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerCaterina De Rosa, Floriana Morgillo, Luisa Amato, et al.
Frontiers in Immunology|February 2, 2024
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern ItalyVito Longo, Carminia Maria Della Corte, Alessandro Russo, et al.
Pageof 14